Prevention or treatment of invasive fungal disease
Conditions
Interventions
Voriconazole for injection:Theraputic drug monitoring
Voriconazole tablet:Theraputic drug monitoring
Posaconazole for injection:Theraputic drug monitoring
Posaconazole enteric-coated tablet:Theraputic drug monitoring
Posaconazole suspension:Theraputic drug monitoring
Sponsors
Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients who intend to take voriconazole or Posaconazole for the prevention or treatment of invasive mycosis; 2. Age 0-18, gender unlimited; 3. The subject and his/her guardian are willing to comply with the procedures and operations specified in the study protocol; 4. The guardian of the subject and the subject of independent informed age are willing and able to provide written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. The subject is known to be allergic to any azole antifungal therapy or other ingredients contained in the study drug; 2. The researcher believes that the condition of the child may interfere with study participation or other inappropriate conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of voriconazole;Plasma concentration of posaconazole; | — |
Secondary
| Measure | Time frame |
|---|---|
| Success rate of IFD prevention or treatment; | — |
Countries
China
Contacts
Public ContactWu Juan
Outcome results
None listed